Fierce Pharma
MAY 2, 2024
Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug. | Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug.
MedCity News
MAY 2, 2024
Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space. The post Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MAY 2, 2024
As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a unique win in previously untreated mantle cell lymphoma (MCL). | AstraZeneca is touting a earlier-than-expected positive readout for Calquence in first-line mantle cell lymphoma. But a big question remains whether it can immediately file with the FDA, especially given the precedent of Imbruvica.
Pharmaceutical Technology
MAY 2, 2024
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
MAY 2, 2024
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday. In turn, the company is eyeing a potential U.S. launch in the fall, which would capitalize on its established commercial efforts in the seasonal COVID-19 immuni
MedCity News
MAY 2, 2024
Kaiser Permanente is deploying Innovaccer’s healthcare AI platform and population health management tools to support better value-based care — starting with its Washington market and potentially expanding to new markets in the future. The post Kaiser Permanente Is Deploying Innovaccer’s Value-Based Care AI Across Washington appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
MAY 2, 2024
Interim results of an ongoing study published in The Lancet have reported that Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalisations by 82 percent in infants under six months, compared to infants who received no RSV intervention. Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.
Fierce Pharma
MAY 2, 2024
Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat chronic obstructive pulmonary disease (COPD) could be delayed, Regeneron CEO Len Schleifer said on Thursday. | Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat COPD could be delayed, as the FDA has requested additional efficacy data from two trials. The regulatory hurdle comes as Eylea showed stagnant sales, even though its new high-dose formula is seeing increased uptake.
MedCity News
MAY 2, 2024
Where we’ve been, where we’re going, and how healthcare organizations can protect themselves from privacy risks caused by the Meta pixel and other third-party trackers The post The Rising Stakes of Healthcare Data Privacy in 2024: The Need for Practical Guidance appeared first on MedCity News.
Fierce Pharma
MAY 2, 2024
Kirk Harmon, Vice President and General Manager, Contract Sales Organization, IQVIA Jave Castillo, Vice President, CSO Solutions, IQVIA | Learn three ways CSO solutions can help your established brands sustain revenue until your new products begin to become profitable.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
MAY 2, 2024
Strategies for building the datasets needed for ACOs to take advantage of artificial intelligence, manage costs and improve outcomes for all The post How ACOs Can Harness AI’s Transformative Potential appeared first on MedCity News.
pharmaphorum
MAY 2, 2024
Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries.
European Pharmaceutical Review
MAY 2, 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023. Following publication of this white paper, the government requested that the MHRA outline the steps the agency is working on in relation to its expectations.
pharmaphorum
MAY 2, 2024
A personalised vaccine for the aggressive brain cancer glioblastoma developed has shown encouraging signs of efficacy in its first human trial.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
MAY 2, 2024
Recent developments in the biologic therapies sector include the authorisation of Pyzchiva ® (biosimilar ustekinumab) by the European Commission, and promising 12-month data for Roche’s subcutaneous injection of OCREVUS ® (ocrelizumab) for relapsing or primary progressive multiple sclerosis. The biologics market is expected to continue its fast growth despite the slowdown in funding observed in the past year.
pharmaphorum
MAY 2, 2024
Sales of Novo Nordisk's obesity drug Wegovy double in Q1, as restrictions on starting doses start to lift in the US.
Pharmaceutical Commerce
MAY 2, 2024
The latest news for pharma industry insiders.
pharmaphorum
MAY 2, 2024
Astellas turns to Poseida again to expand its CAR-T pipeline, adding two projects in solid tumours in a deal worth up to $600 million
PharmaTimes
MAY 2, 2024
The inherited disorder is caused by genetic mutations that affects haemoglobin production
pharmaphorum
MAY 2, 2024
Novartis has struck another deal in radiopharmaceuticals, agreeing to pay $1bn upfront for radioligand therapy developer Mariana Oncology.
MedCity News
MAY 2, 2024
Some specific topics that should be prioritized at all levels The post How Companies Can Improve Their Learning and Development Strategy and Why it is Essential in the Life Sciences Space appeared first on MedCity News.
PharmaTimes
MAY 2, 2024
Bacteroides fragilis in the gut improves immunity and immunotherapy treatment responses
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
MAY 2, 2024
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
Copyright Clearance Center
MAY 2, 2024
May 2, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announced today that it has earned five 2023 Top Workplaces Culture Excellence Awards from Energage LLC for Compensation & Benefits; Leadership; Work-Life Flexibility; Innovation; and Purpose & Values for the second consecutive year.
PharmaVoice
MAY 2, 2024
Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions.
Pharmaceutical Technology
MAY 2, 2024
Xyphos Biosciences and Poseida Therapeutics have signed a deal to develop new allogeneic cell therapies for treating cancer.
PharmaTech
MAY 2, 2024
Guidance documents and interaction with FDA can help manufacturers stay in GMP compliance, says Siegfried Schmitt, VP Technical, at Parexel.
Pharmaceutical Technology
MAY 2, 2024
As the obesity space becomes more congested, clinical trial recruitment has become a larger issue for small biotechs.
PharmaTech
MAY 2, 2024
The report covers the major achievements of the office during 2023, including notable drug approvals, publications, guidances, workshops, webinars, and meetings.
Pharmacy Times
MAY 2, 2024
Currently, the treatment is being evaluated in the phase 3 CALYPSO study to further prove the safety and efficacy in patients with hypoparathyroidism.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
310 
Let's personalize your content